Hookipa Pharma (HOOK) Receives a Hold from RBC Capital
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2025
0mins
Source: Business Insider
Analyst Rating and Price Target: RBC Capital analyst Brian Abrahams has maintained a Hold rating on Hookipa Pharma with a price target of $2.00, while the company's shares closed at $1.41.
Company Financial Performance: Hookipa Pharma reported a quarterly revenue of $4.7 million and a GAAP net loss of $13.84 million for the quarter ending September 30, showing an improvement from last year's revenue of $6.87 million and a net loss of $19.07 million.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
